ETIOPATHOGENETIC SIGNIFICANCE OF MAO-B INHIBITORS IN PARKINSON’S DISEASE AND THEIR ROLE IN REDUCING MOTOR SYMPTOMS

KHAKIMOVA Sakhiba Ziyadulloyevna, GAFFAROVA Parvina Abdurafikovna

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali · 2026-yil

Annotatsiya

MAO-B inhibitors increase synaptic dopamine levels by slowing dopamine metabolism, reduce oxidative stress, and exert neuroprotective effects. When used as monotherapy in the early stages of Parkinson’s disease and in combination with levodopa at later stages, they significantly reduce motor symptoms such as bradykinesia, rigidity, and tremor, and are considered pathogenetic therapeutic agents with the potential to slow disease progression.

Maqola ma’lumotlari
MualliflarKHAKIMOVA Sakhiba Ziyadulloyevna, GAFFAROVA Parvina Abdurafikovna
JurnalJournal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali
Nashr sanasi2026-04-21
Jild11
Son1
TilO‘zbek

Kalit so‘zlar

нейродегенеративные заболевания, ЭМГ, дофамин, neurodegenerative diseases, EMG, dopamine, нейродегенератив касалликлар, ЭМГ, допамин

Ilmiy soha

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali jurnalidan boshqa maqolalar

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali — barcha maqolalar